Bayer Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bill Anderson

Amministratore delegato

€11.8m

Compenso totale

Percentuale dello stipendio del CEO	14.3%
Mandato del CEO	1.6yrs
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bill Anderson rispetto agli utili di Bayer?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

Compensazione vs Mercato: La retribuzione totale di Bill ($USD 12.43M ) è superiore alla media delle aziende di dimensioni simili nel mercato Austrian ($USD 4.29M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Bill con le performance aziendali.

AMMINISTRATORE DELEGATO

Bill Anderson (58 yo)

1.6yrs

Mandato

€11,804,104

Compensazione

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
William Anderson	Chairman of the Management Board & CEO	1.6yrs	€11.80m	Nessun dato
Wolfgang Nickl	CFO & Member of Management Board	6.6yrs	€3.42m	Nessun dato
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	6yrs	€3.43m	Nessun dato
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.8yrs	€3.65m	Nessun dato
Heike Prinz	Chief Talent Officer	1.2yrs	€2.53m	Nessun dato
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	Nessun dato	Nessun dato
Sebastian Guth	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Amanda McClerren	Chief Information Officer	less than a year	Nessun dato	Nessun dato
Jost Reinhard	Head of Investor Relations	1.1yrs	Nessun dato	Nessun dato
Thomas Laubert	Head of Law	1.3yrs	Nessun dato	Nessun dato
Michael Preuss	Head of Communications	8.5yrs	Nessun dato	Nessun dato
Bernd-Peter Bier	Head of Group Finance	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di BAYN non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul M. Achleitner	Member of Supervisory Board	22.6yrs	€225.00k	Nessun dato
Ertharin Cousin	Independent Member of the Supervisory Board	5.1yrs	€270.00k	Nessun dato
Heinz Webers	Employee Representative Member of Supervisory Board	2.6yrs	€205.00k	Nessun dato
Simone Bagel-Trah	Independent Member of Supervisory Board	10.6yrs	€227.00k	Nessun dato
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	Nessun dato	Nessun dato
Lori Schechter	Independent Supervisory Board Member	less than a year	Nessun dato	Nessun dato
Horst Baier	Independent Member of Supervisory Board	4.6yrs	€333.00k	Nessun dato
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.6yrs	€346.00k	Nessun dato
André van Broich	Member of Supervisory Board	12.6yrs	€271.00k	Nessun dato
Otmar Wiestler	Independent Member of Supervisory Board	10.1yrs	€237.00k	Nessun dato
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.5yrs	€509.00k	Nessun dato
Gunter Hilken	Chairman of Executive Board - Currenta	no data	Nessun dato	Nessun dato

7.0yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BAYN sono considerati esperti (durata media dell'incarico 7 anni).

Bayer Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Bayer AG Announces CEO Changes

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

New major risk - Share price stability

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

New minor risk - Share price stability

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

New major risk - Share price stability

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.66 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings released: EPS: €2.22 (vs €3.35 in 1Q 2022)

Upcoming dividend of €2.40 per share at 4.0% yield

Full year 2022 earnings released: EPS: €4.22 (vs €1.02 in FY 2021)

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media